Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925417 · ClinicalTrials.gov registry record · Phase 2
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
A Phase 2 study of Recurrent Clostridium Difficile Infection, sponsored by Rebiotix.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 13
- Study locations
NCT01925417 is a Phase 2 study of Recurrent Clostridium Difficile Infection that has completed, run by Rebiotix. The registered enrollment target is 34 participants. The trial reports 13 study locations across 11 states.
The verdict
NCT01925417, a Phase 2 study of Recurrent Clostridium Difficile Infection, has completed, sponsored by Rebiotix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.
Conditions Studied
Interventions
- BIOLOGICAL RBX2660 (microbiota suspension)
Study Locations (13)
Illinois
- Edward Hines Jr VA Hospital (veterans only) - Chicago
- University of Chicago - Chicago
Michigan
- Detroit Medical Center - Detroit
- Henry Ford Health System - Detroit
Arizona
- Mayo Clinic Arizona - Phoenix
Colorado
- Denver Health and University of Colorado - Denver
Florida
- Borland-Groover Clinic - Jacksonville
Louisiana
- Ochsner Clinic - New Orleans
Maryland
- Chevy Chase Clinical Research - Chevy Chase
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2013-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925417
The ClinicalTrials.gov registry entry for NCT01925417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rebiotix, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Clostridium Difficile Infection appearing as the primary indexed condition, and to 1 intervention - of which RBX2660 (microbiota suspension) is the first listed.
NCT01925417 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Illinois, Michigan, Arizona.
Frequently Asked Questions
What is clinical trial NCT01925417 about?
NCT01925417 is a clinical study titled "Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea". This study will assess the safety of a new biologic drug, RBX2660 (microbiota suspension) as a treatment for recurrent Clostridium difficile-associated diarrhea (CDAD), which is the primary symptom of recurrent Clostridium difficile infection. All eligible subjects will receive RBX2660.
What is the current status of trial NCT01925417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2013-08. Estimated completion is 2014-07.
What conditions does trial NCT01925417 study?
This clinical trial studies the following conditions: Recurrent Clostridium Difficile Infection.
What interventions are being tested in trial NCT01925417?
The interventions under investigation include: RBX2660 (microbiota suspension) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01925417?
This trial is sponsored by Rebiotix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01925417 being conducted?
This trial has 13 study locations across Arizona, Colorado, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Clostridium Difficile Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.